China Pharma has developed a diversified portfolio of therapeutic products with strong market potential and maintains strong relationships with leading research institutions in China. The Company continues to expand its marketing channels by growing its sales force. In addition, the China SFDA has resumed normal procedures for approving new drugs. Therefore, the Company's management believes that revenue will grow at least 40%, and to $46.5 million in 2008.
Conference Call and Webcast
The Company will conduct a conference call to discuss the fourth quarter 2007 results today, March 31, 2008, at 11:00 am EDT. Listeners may access the call by dialing 1-800-762-8908, conference ID 3862567. This conference call will be broadcast live over the Internet and can be accessed by clicking this link: http://www.wsw.com/webcast/cc/cphi/ . A replay of the call will also be available shortly after the call on China Pharma's website http://www.chinapharmaholdings.com for 90 days.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement:
Certain statements in this press release and oral statements made by
China Pharma on its conference call in relation to this release, constitute
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved